These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8027415)

  • 21. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study.
    Devanand DP; Cooper T; Sackeim HA; Taurke E; Mayeux R
    Psychopharmacol Bull; 1992; 28(2):169-73. PubMed ID: 1513920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
    Ericksen SE; Hurt SW; Chang S
    Psychopharmacol Bull; 1978 Apr; 14(2):15-6. PubMed ID: 349597
    [No Abstract]   [Full Text] [Related]  

  • 31. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug holidays and serum haloperidol levels in schizophrenic patients.
    McMillan DE; Fody EP; Couch L; Harrison RH; Newton JE; Reese WG
    J Clin Psychiatry; 1986 Jul; 47(7):373-4. PubMed ID: 3722135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Psychopharmacol Bull; 1988; 24(1):172-5. PubMed ID: 3387519
    [No Abstract]   [Full Text] [Related]  

  • 36. Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
    Potkin SG; Shen YC; Zhou DF; Pardes H; Shu L; Phelps B; Poland R
    Psychopharmacol Bull; 1985; 21(1):59-61. PubMed ID: 3983339
    [No Abstract]   [Full Text] [Related]  

  • 37. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of haloperidol and clinical response.
    Van Putten T; Marder SR; May PR; Poland RE; O'Brien RP
    Psychopharmacol Bull; 1985; 21(1):69-72. PubMed ID: 3920705
    [No Abstract]   [Full Text] [Related]  

  • 40. Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
    Dysken MW; Kim SW; Vatassery G; Johnson SB; Skare S; Holden L; Thomsyck L
    J Clin Psychopharmacol; 1992 Apr; 12(2):128-32. PubMed ID: 1573034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.